CA2378913A1 - System for effecting smoke cessation - Google Patents

System for effecting smoke cessation Download PDF

Info

Publication number
CA2378913A1
CA2378913A1 CA002378913A CA2378913A CA2378913A1 CA 2378913 A1 CA2378913 A1 CA 2378913A1 CA 002378913 A CA002378913 A CA 002378913A CA 2378913 A CA2378913 A CA 2378913A CA 2378913 A1 CA2378913 A1 CA 2378913A1
Authority
CA
Canada
Prior art keywords
formulation
nicotine
containers
patient
aerosolizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002378913A
Other languages
French (fr)
Other versions
CA2378913C (en
Inventor
Stephen J. Farr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aradigm Corp
Original Assignee
Aradigm Corporation
Stephen J. Farr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aradigm Corporation, Stephen J. Farr filed Critical Aradigm Corporation
Publication of CA2378913A1 publication Critical patent/CA2378913A1/en
Application granted granted Critical
Publication of CA2378913C publication Critical patent/CA2378913C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
    • A24F40/42—Cartridges or containers for inhalable precursors
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/06—Packaging for specific medical equipment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A system is disclosed which makes it possible for a patient to be delivered gradually reduced amounts of nicotine over time thereby allowing the patient to be gradually weaned off of dependence on nicotine and quit smoking. The system is comprised of a means for aerosolizing a formulation and containers of formulation. The formulation is comprised of nicotine in a pharmaceutically acceptable carrier. Preferably, a plurality of containers are produced wherein the concentration of nicotine in the different containers oR different groups of containers is reduced. The patient uses containers with the highest concentration initially and gradually moves towards using containers with lower and lower concentrations of nicotine until the patient's dependence on nicotine is eliminated.

Claims (21)

What is claimed is:
1. A system for aiding a patient in quitting smoking, comprising:
a device for aerosolizing a formulation;
a first plurality of containers which are designed for being loaded into the device for aerosolizing formulation wherein the containers are comprised of nicotine and a pharmaceutically acceptable carrier and wherein the nicotine is present in a first concentration;
a second plurality of containers capable of being loaded into the device for aerosolizing formulation wherein the formulation in the second plurality of containers is comprised of nicotine and a pharmaceutically acceptable carrier and further wherein the nicotine is present in the formulation in a second concentration which is less than the first concentration.
2. The system of claim 1, further comprising:
a third plurality of containers which are designed for being loaded into the device for aerosolizing formulation wherein the containers are comprised of nicotine and a pharmaceutically acceptable carrier and wherein the nicotine is present in a third concentration which is less than the second concentration.
3. The system as claimed in claim 1, wherein the formulation in the first plurality of containers and the formulation in the second plurality of containers is a liquid flowable formulation wherein the nicotine is present in the formulation in a solution or suspension.
4. The system as claimed in claim 3, wherein the first plurality of containers comprises a porous membrane for each container and further wherein the second plurality of containers comprises a porous membrane for each container.
5. The system as claimed in claim 1, wherein the formulation in the first plurality of containers and the formulation in the second plurality of containers is a dry powder formulation.
The system as claimed in claim 1, wherein the first plurality of containers comprises two or more canisters which canisters contain the formulation in the form of nicotine and low boiling point propellant and wherein the second plurality of containers comprises two or more canisters wherein the formulation in the canisters comprises nicotine and a low boiling point propellant.
7. The system as claimed in claim 1, wherein the device for aerosolizing formulation is a hand-held, self contained device.
8. The system as claimed in claim 1, wherein the first plurality of containers each comprise a porous membrane wherein the pores have a first average size, and wherein the second plurality of containers each comprise a porous membrane wherein the pores have a second average size which is larger than the first average size of the pores in the membrane of the first plurality of containers.
9. A device for aerosolizing a nicotine formulation, comprising:
a means for aerosolizing formulation by applying force; and a means for adjusting the means for aerosolizing formulation so that a different amount of force can be applied based on the adjustment.
10. The device as claimed in claim 9, further comprising:
a container loaded into the device which container is comprised of a formulation comprised of nicotine and a pharmaceutically acceptable carrier.
11. A kit for aiding a patient in quitting smoking, comprising:
a first plurality of containers having therein nicotine and a pharmaceutically acceptable carrier, wherein the nicotine is present in a first concentration;
a second plurality of containers having therein nicotine and a pharmaceutically acceptable carrier wherein the nicotine is present in a second concentration which is less than the first concentration.
12. The kit as claimed in claim 11, wherein the first plurality of containers and second plurality of containers hold the nicotine and pharmaceutically acceptable carrier in a liquid flowable form.
13. The kit as claimed in claim 11, wherein the first plurality of containers and second plurality of containers each hold the nicotine and pharmaceutically acceptable carrier in a dry powder form.
14. A method of treatment, comprising:
(a) aerosolizing a formulation comprised of nicotine creating aerosolized particles which are sufficiently small as to target the alveoli of a patient's respiratory tract;
(b) allowing the patient to inhale the aerosolized particles of (a) thereby causing nicotine to enter the patient's blood;
(c) repeating (a) and (b) a plurality of times;
(d) aerosolizing a formulation comprised of nicotine creating aerosolized particles which are sized in order to target the bronchioles of the patient's respiratory tract;
(e) allowing the patient to inhale the aerosolized particles of (d) thereby targeting the bronchioles of the respiratory tract; and (f) repeating (d) and (e) a plurality of times.
15. The method of claim 14, further comprising:
(g) aerosolizing a formulation comprised of nicotine creating aerosolized particles which are sized in order to target the bronchi of the patient's respiratory tract;
(h) allowing the patient to inhale the aerosolized particles of (g) into the bronchi of the respiratory tract; and (i) repeating (g) and (h) a plurality of times.
16. The method of claim 14, wherein the formulation is a liquid formulation comprising nicotine and an excipient selected from the group consisting of an aqueous solvent to form solutions and a liquid to form suspensions.
17. The method of claim 14, wherein the formulation comprises a solution or suspension of a nicotine and an aqueous solvent or liquid carrier and the aerosolized particles are created by moving the formulation through a porous membrane.
18. A method of treatment, comprising:
(a) aerosolizing a formulation comprising about 0.25 mg or more of nicotine to create aerosolized particles which target an area of a patient's respiratory tract;
(b) allowing the patient to inhale the aerosolized particles of (a) thereby causing nicotine to enter the patient's blood;
(c) repeating (a) and (b) a plurality of times.
19. The method of claim 18, further comprising:
(d) aerosolizing a formulation comprising about 0.25 mg or more of nicotine to create aerosolized particles which target a second area of the patient's respiratory tract;
(e) allowing the patient to inhale the aerosolized particles of (d) to the second area of the patient's respiratory tract; and (f) repeating (d) and (e) a plurality of times.
20. A method comprising the steps of:
(a) aerosolizing a formulation comprised of nicotine creating aerosolized particles having a diameter of 0.5 µ, to about 2 µ;
(b) allowing the patient to inhale the aerosolized particles of (a) into the patient's respiratory tract;
(c) repeating (a) and (b) a plurality of times;
(d) aerosolizing a formulation comprised of nicotine creating aerosolized particles having a diameter of 2 µ to about 4 µ;
(e) allowing the patient to inhale the aerosolized particles of (d) into the patient's respiratory tract; and (f) repeating (d) and (e) a plurality of times.
21. The method of claim 20, further comprising the steps of:
(g) aerosolizing a formulation comprised of nicotine creating aerosolized particles having a diameter of 4 µ, to about 8 µ;
(h) allowing the patient to inhale the aerosolized particles of (g) into the patient's respiratory tract; and (i) repeating (g) and (h) a plurality of times.
CA2378913A 1999-07-16 2000-07-12 System for effecting smoke cessation Expired - Fee Related CA2378913C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14414099P 1999-07-16 1999-07-16
US60/144,140 1999-07-16
PCT/US2000/019034 WO2001005459A1 (en) 1999-07-16 2000-07-12 System for effecting smoke cessation

Publications (2)

Publication Number Publication Date
CA2378913A1 true CA2378913A1 (en) 2001-01-25
CA2378913C CA2378913C (en) 2010-02-23

Family

ID=22507255

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2378913A Expired - Fee Related CA2378913C (en) 1999-07-16 2000-07-12 System for effecting smoke cessation

Country Status (6)

Country Link
US (1) US20020179102A1 (en)
EP (1) EP1218048A4 (en)
JP (1) JP4999245B2 (en)
AU (1) AU777326B2 (en)
CA (1) CA2378913C (en)
WO (1) WO2001005459A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6595210B2 (en) * 2000-11-27 2003-07-22 Unisia Jecs Corporation Inhalator for administering powder composition
EP1392258B1 (en) 2001-05-24 2008-11-26 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (en) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
AU2002363947A1 (en) 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
CN100381083C (en) 2003-04-29 2008-04-16 韩力 Electronic nonflammable spraying cigarette
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
CN2719043Y (en) 2004-04-14 2005-08-24 韩力 Atomized electronic cigarette
WO2006004646A1 (en) * 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
FR2873584B1 (en) * 2004-08-02 2006-11-17 Jean Jacques Hubinois TOBACCO WEANING SYSTEM
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchronous transdermal drug delivery
CN201067079Y (en) 2006-05-16 2008-06-04 韩力 Simulation aerosol inhaler
EP2086317A4 (en) * 2006-12-01 2010-03-03 Aradigm Corp Nicotine formulations, kits and systems and methods for their use
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CN201379072Y (en) 2009-02-11 2010-01-13 韩力 Improved atomizing electronic cigarette
US20120048963A1 (en) 2010-08-26 2012-03-01 Alexza Pharmaceuticals, Inc. Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US9907748B2 (en) * 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US20140261488A1 (en) * 2013-03-15 2014-09-18 Altria Client Services Inc. Electronic smoking article
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
DK3268072T3 (en) 2015-03-11 2024-01-22 Alexza Pharmaceuticals Inc USE OF ANTISTATIC MATERIALS IN THE AIRWAY FOR THERMAL AEROSOL CONDENSATION PROCESS
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US10433580B2 (en) 2016-03-03 2019-10-08 Altria Client Services Llc Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge
US10455863B2 (en) 2016-03-03 2019-10-29 Altria Client Services Llc Cartridge for electronic vaping device
US10368580B2 (en) 2016-03-08 2019-08-06 Altria Client Services Llc Combined cartridge for electronic vaping device
US10368581B2 (en) 2016-03-11 2019-08-06 Altria Client Services Llc Multiple dispersion generator e-vaping device
US10357060B2 (en) 2016-03-11 2019-07-23 Altria Client Services Llc E-vaping device cartridge holder
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
GB2604314A (en) 2017-09-22 2022-09-07 Nerudia Ltd Device, system and method
EP3758528A1 (en) * 2018-02-26 2021-01-06 Nerudia Limited Device, system and method
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Drug delivery methods and systems
LU101510B1 (en) * 2019-12-02 2021-06-04 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of an aerosol and dispensing device

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284089A (en) * 1978-10-02 1981-08-18 Ray Jon P Simulated smoking device
US4393884A (en) * 1981-09-25 1983-07-19 Jacobs Allen W Demand inhaler for oral administration of tobacco, tobacco-like, or other substances
US4474191A (en) * 1982-09-30 1984-10-02 Steiner Pierre G Tar-free smoking devices
DE3241437A1 (en) * 1982-11-10 1984-05-10 Ferdinand Prof. Dr.med. 6901 Wilhelmsfeld Schmidt Composition for stopping smoking and/or for intake of nicotine without side effects by addicted smokers
US4813437A (en) * 1984-01-09 1989-03-21 Ray J Philip Nicotine dispensing device and method for the manufacture thereof
US4800903A (en) * 1985-05-24 1989-01-31 Ray Jon P Nicotine dispenser with polymeric reservoir of nicotine
US4715387A (en) * 1985-08-23 1987-12-29 The Regents Of The Univ. Of California Aerosol for use in the reduction of tobacco smoking
US4793366A (en) * 1985-11-12 1988-12-27 Hill Ira D Nicotine dispensing device and methods of making the same
US4917120A (en) * 1986-05-21 1990-04-17 Advanced Tobacco Products, Inc. Nicotine impact modification
GB8614805D0 (en) * 1986-06-18 1986-07-23 British American Tobacco Co Aerosol device
US4735217A (en) * 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4765348A (en) * 1986-12-12 1988-08-23 Brown & Williamson Tobacco Corporation Non-combustible simulated cigarette device
US5834011A (en) * 1988-02-19 1998-11-10 The Regents Of The University Of California Method for aiding in the reduction of incidence of tobacco smoking
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
US5167242A (en) * 1990-06-08 1992-12-01 Kabi Pharmacia Aktiebolaq Nicotine-impermeable container and method of fabricating the same
JP3661131B2 (en) * 1992-02-20 2005-06-15 アスペン ファーマケア ヨーロッパ リミテッド Smoking suppression device
US6024097A (en) * 1992-02-20 2000-02-15 J Mom Trust Product for assisting a smoker in giving up the habit
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
WO1995001137A1 (en) * 1993-06-29 1995-01-12 Voges Innovation Pty. Ltd. Dispenser
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
SE9303574D0 (en) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method of manufacturing thereof
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
US5906202A (en) * 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6196218B1 (en) * 1999-02-24 2001-03-06 Ponwell Enterprises Ltd Piezo inhaler

Also Published As

Publication number Publication date
CA2378913C (en) 2010-02-23
JP2003504165A (en) 2003-02-04
EP1218048A4 (en) 2009-08-26
AU5931200A (en) 2001-02-05
JP4999245B2 (en) 2012-08-15
US20020179102A1 (en) 2002-12-05
AU777326B2 (en) 2004-10-14
EP1218048A1 (en) 2002-07-03
WO2001005459A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
CA2378913A1 (en) System for effecting smoke cessation
EP1061901B1 (en) Nicotine inhaler
EP1458252B1 (en) Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity
CA2127253C (en) Composition to help stop smoking
Shah et al. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance
US6660715B2 (en) Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
PT1143931E (en) Pulmonary drug delivery
US20180256560A1 (en) Liquid nicotine formulation
EP1874279A2 (en) Water-soluble films comprising nicotine
US20120042886A1 (en) Method of producing a nicotine medicament and a medicament made by the method
KR20010101991A (en) Compressed air inhaler for pulmonary application of liposomal powder aerosols and powder aerosols suitable therefor
WO2002003998A3 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
CA2966637C (en) Rapamycin powders for pulmonary delivery
GB2030862A (en) A composition for treating drug addiction such as smoking nicotine-containing products
EP1988956A2 (en) System for delivering nebulized cyclosporine and methods of treatment
ES2339423T3 (en) THERAPEUTIC COMPOSITIONS FOR PULMONARY ADMINISTRATION.
Niven et al. Solute absorption from the airways of the isolated rat lung. II. Effect of surfactants on absorption of fluorescein
EP3993646B1 (en) An oral pouched nicotine product including a filling material comprising nicotine-containing particles
EP0359195A3 (en) Controlled release therapeutic system for liquid pharmaceutical formulations
FR2873584A1 (en) System of nicotine inhaler, useful to release nicotine, comprises pressurized compartment, oral inhalation chamber and diffusion nozzle
CA2265198C (en) Method of producing a nicotine medicament and a medicament made by the method
CN114554876B (en) Improved tobacco flavor dry powder formulations
WO2001015777A1 (en) Pulmonary-administration of mineral ascorbates
CN105640896B (en) The method for preparing the product comprising stabilizing active object and the composition comprising identical active matter
EP3721723A1 (en) A carrier and a method of use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180712